Literature DB >> 16227037

The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome.

Judith L Ross1, Karen Kowal, Charmian A Quigley, Werner F Blum, Gordon B Cutler, Brenda Crowe, Karine Hovanes, Frederick F Elder, Andrew R Zinn.   

Abstract

OBJECTIVE: To evaluate the growth disorder and phenotype in prepubertal children with Leri-Weill dyschondrosteosis (LWD), a dominantly inherited skeletal dysplasia, and to compare the findings from girls with Turner syndrome (TS). STUDY
DESIGN: We studied the auxologic and phenotypic characteristics in 34 prepubertal LWD subjects (ages 1 to 10 years; 20 girls, 14 boys) with confirmed short stature homeobox-containing gene (SHOX) abnormalities. For comparative purposes, we evaluated similar physical and growth parameters in 76 girls with TS (ages 1 to 19 years) and 24 girls with LWD (ages 1 to 15 years) by using data collected from the postmarketing observational study, GeNeSIS.
RESULTS: In the clinic sample LWD subjects, height standard deviation score ranged from -5.5 to +0.1 (-2.3 +/- 1.3, girls and -1.8 +/- 0.6, boys). Wrist changes related to Madelung deformity were present in 18 of 34 (53%) LWD subjects. In comparing the LWD and TS populations in the GeNeSIS sample, Madelung deformity, increased carrying angle, and scoliosis were more prevalent in the LWD population, whereas high arched palate was similarly prevalent in the two populations.
CONCLUSIONS: Short stature is common in both LWD (girls and boys) and TS (girls). Clinical clues to the diagnosis of SHOX haploinsufficiency in childhood include short stature, short limbs, wrist changes, and tibial bowing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227037     DOI: 10.1016/j.jpeds.2005.04.069

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Evaluation of the azoospermic male.

Authors:  Robert Oates
Journal:  Asian J Androl       Date:  2011-12-19       Impact factor: 3.285

2.  A mouse model for human short-stature syndromes identifies Shox2 as an upstream regulator of Runx2 during long-bone development.

Authors:  John Cobb; Andrée Dierich; Yolande Huss-Garcia; Denis Duboule
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

3.  Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.

Authors:  C R Holroyd; J H Davies; P Taylor; K Jameson; C Rivett; C Cooper; E M Dennison
Journal:  Osteoporos Int       Date:  2010-02-05       Impact factor: 4.507

4.  Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial.

Authors:  Imane Benabbad; Myriam Rosilio; Christopher J Child; Jean-Claude Carel; Judith L Ross; Cheri L Deal; Stenvert L S Drop; Alan G Zimmermann; Nan Jia; Charmian A Quigley; Werner F Blum
Journal:  Horm Res Paediatr       Date:  2016-12-22       Impact factor: 2.852

5.  Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency.

Authors:  Gudrun Rappold; Werner F Blum; Elena P Shavrikova; Brenda J Crowe; Ralph Roeth; Charmian A Quigley; Judith L Ross; Beate Niesler
Journal:  J Med Genet       Date:  2006-12-20       Impact factor: 6.318

Review 6.  Fracture risk and bone mineral density in Turner syndrome.

Authors:  Vladimir K Bakalov; Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2008-04-15       Impact factor: 6.514

Review 7.  Emerging options in growth hormone therapy: an update.

Authors:  Stephen F Kemp; J Paul Frindik
Journal:  Drug Des Devel Ther       Date:  2011-08-30       Impact factor: 4.162

8.  Different skeletal phenotypes in a mother and two daughters with short stature homeobox-containing haploinsufficiency.

Authors:  Keisuke Nagasaki; Toru Kikuchi; Makoto Uchiyama
Journal:  Clin Pediatr Endocrinol       Date:  2007-08-08

9.  Recombinant human growth hormone in the treatment of Turner syndrome.

Authors:  Bessie E Spiliotis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.